Novel Combination Boosts Survival in Unresectable Liver Cancer
The PD-1 inhibitor camrelizumab combined with the VEGFR2-targeted inhibitor rivoceranib (also known as apatinib) significantly improved survival compared with sorafenib (Nexavar) alone for the treatment of patients with unresectable hepatocellular carcinoma (HCC), a randomized phase III trial showed. At a median follow-up of 7.8 months, the median progression-free survival was 5.6 months with the two […]